Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Sutro Biopharma, Inc.NASDAQ: STRO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$27.75M, compared with -$45.57M a year earlier. Trailing-twelve-month EBITDA was -$106.12M.
Context
- EBITDA amounted to 142.1% of revenue in FY2025, down 148.7 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$28.89M (+80.2%) for the fiscal year ending Dec 2026, a step up from the +19.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.75M+20.5% QoQ
- Last fiscal yearDec 2025
- -$145.65M+19.3% YoY
- LTMMar 2026
- -$106.12M+42.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +39.1% | -2451.9% | -2491.0 pp |
| 1 year | +19.3% | +80.2% | +60.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (145.65M) USD
- Year-over-year change
- +19.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (145.65M) | +19.3% |
| FY2024 | 2024-12-31 | (180.45M) | -165.7% |
| FY2023 | 2023-12-31 | (67.92M) | +35.4% |
| FY2022 | 2022-12-31 | (105.07M) | -7.7% |
| FY2021 | 2021-12-31 | (97.56M) | — |
EBITDA vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +42.0% is the 2nd highest of 9, against a peer median of -9.8%.
- EBITDA amounts to 106.5% of revenue for STRO, versus a peer median of 44951.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$40.42M USD | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$44.08M USD | +36.5% | — | — |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M USD | -35.4% | — | — |
| LTM Mar 2026 | -$106.12M USD | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$106.88M USD | -21.2% | — | — | |
| LTM Mar 2026 | -$107.98M USD | +49.6% | — | — | |
| Peer median (excluding STRO) | — | -9.8% | — | 44951.4% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| Weighted Avg Shares | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
| Weighted Avg Shares (Diluted) | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.